文献速递脑血管病帕金森病与运动障碍神经肌肉病

新上市神经科药物的费用与使用情况

Costs and Utilization of New-to-Market Neurologic Medications.
PubMed 文献 · Neurology · 2022-11-30

该研究利用2001至2019年医疗药品索赔数据库,比较11种神经系统疾病中新上市药物与现有指南支持药物的使用和费用。多数新上市药物使用比例低(除1种疾病外均低于20%),自付和标准化总费用显著更高。2019年30天供应量自付费用中位数最高为依达拉奉和依库珠单抗。

要点

  • 多数新上市神经科药物使用比例低,除1种疾病外均低于20%。
  • 新上市药物的自付费用和标准化总费用显著高于现有指南支持药物。
  • 2019年依达拉奉30天供应量自付费用中位数为712.8美元。

核心结论

  • 尽管FDA批准的神经科药物数量增加,新批准药物在私人保险人群中的使用仍然很少。
  • 鉴于大多数新药费用高且疗效相似,有限的使用可能是合适的。
  • 对于疗效更大的新药,需要未来研究确定高费用是否是用药障碍。

研究设计与样本

  • 使用2001至2019年医疗药品索赔数据库的回顾性分析。
  • 纳入11种神经系统疾病患者,比较新上市药物与现有指南支持药物的使用和费用。
  • 新上市药物定义为2014至2018年间获FDA批准的所有神经科药物。

主要发现

  • 多数新上市药物使用比例低,除1种疾病外均低于20%。
  • 新上市药物的自付费用和标准化总费用显著更高。
  • 2019年30天供应量自付费用中位数最高为依达拉奉712.8美元(第25百分位59.8美元,第75百分位802.0美元)。
  • 依库珠单抗30天供应量自付费用中位数为91.1美元(第25百分位3.0美元,第75百分位3216.4美元)。
  • 新上市药物自付费用分布高度变异,时间趋势不可预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The objective of this study was to compare the utilization and costs (total and out-of-pocket) of new-to-market neurologic medications with existing guideline-supported neurologic medications over time. METHODS: We used a healthcare pharmaceutical claims database (from 2001 to 2019) to identify patients with both a diagnosis of 1 of 11 separate neurologic conditions and either a new-to-market medication or an existing guideline-supported medication for that condition. Neurologic conditions included orthostatic hypotension, spinal muscular atrophy, Duchenne disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, Huntington disease, tardive dyskinesia, transthyretin amyloidosis, and migraine. New-to-market medications were defined as all neurologic medications approved by the US Food and Drug Administration (FDA) between 2014 and 2018. In each year, we determined the median out-of-pocket and standardized total costs for a 30-day supply of each medication. We also measured the proportion of patients receiving new-to-market medications compared with all medications specific for the relevant condition. RESULTS: We found that the utilization of most new-to-market medications was small (<20% in all but 1 condition), compared with existing, guideline-supported medications. The out-of-pocket and standardized total costs were substantially larger for new-to-market medications. The median (25th percentile, 75th percentile) out-of-pocket costs for a 30-day supply in 2019 were largest for edaravone ($712.8 [$59.8-$802.0]) and eculizumab ($91.1 [$3.0-$3,216.4]). For new-to-market medications, the distribution of out-of-pocket costs was highly variable and the trends over time were unpredictable compared with existing guideline-supported medications. DISCUSSION: Despite the increasing number of FDA-approved neurologic medications, utilization of newly approved medications in the privately insured population remains small. Given the high costs and similar efficacy for most of the new medications, limited utilization may be appropriate. However, for new medications with greater efficacy, future studies are needed to determine whether high costs are a barrier to utilization.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Reynolds EL, Gallagher G, Hill CE, et al. Costs and Utilization of New-to-Market Neurologic Medications. Neurology. 2022. PMID: 36450601. doi:10.1212/WNL.0000000000201627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。